Drug intelligence / Profile preview

compound 55

Development stage: Preclinical
Modality: Small Molecules

Overview

Compound 55 is a novel macrocyclic derivative that functions as a potent inhibitor of ATP-citrate lyase (ACLY), a key lipogenic enzyme involved in the synthesis of fatty acids and cholesterol. It has demonstrated strong ACLY inhibitory activity (IC50 = 8.3 nM), high binding affinity to ACLY, favorable pharmacokinetic profiles, and potent hypolipidemic effects in vivo. This compound is being developed as a potential therapeutic candidate for the treatment of hyperlipidemia and related diseases.

Other names: 2,8-disubstituted-1,5-naphthyridine derivative

Targets

ACLY (ATP-citrate synthase)

Beyond the preview

Go deeper on compound 55.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on compound 55.

Explore the full profile